that is why pharmas are going down...too much generic coming in the market, companies killing each other for pricing. There is no quick fix for this....
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Frovatriptan Succinate Tablets 2.5 mg, a generic version of Endo's Frova® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used to treat acute migraine headaches in adults.
do a hostile takeover at $25...still almost a double from here.
At some point during summer I see M&A picking up big ....prices too low for this not to happen.
no sir, they are not going bankrupt..go read their earnings transcript.
a LOT is priced in already. Go read their earnings transcript....150 products waiting FDA approval, Lots of exciting products coming later in 2016. A 20% drop in earnings does not equate to 50% drop in stock price. All metrics are VERY cheap. P/B, P/S, P/E.
deeply oversold...average target AFTER Friday warning is about $27-30
Should the company decide to dissolve, the book value per common indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid.
price to book under 0.5, book value is over $26. Someone will scoop them up quick.
hopefully he is happy.
some stats -
price/book value - 0.5
price/sales - 1
P/E for next year - 2.7
This is CRAZY !!! vrx is overvalued compared this this much more.
CEO needs to buy shares, so do directors.
CEO needs to start looking at strategic - look for suitors, mergers. At 0.5 book value, this is too cheap and a robust pipeline later this year. He already said board is investor friendly. More generic drug companies needs to merge.
Now at 0.5 times book value, this will be easily and quickly bought out. It has over 100 products in pipeline over next 2-3 years.
book value so low. Its book value is DOUBLE current price. This is just crazy.
incredible beatdown mean strong rebound...even if the just meet the numbers. But again they really lowered it, so beating is going to be easy.
yet VRX has so many other issues...sec investigating, senate, jacking up prices, accounting practices.
Endo has none of this. Much cleaner company, with robust pipeline.
In 5 months ENDP will not be a stand alone company...there will be M&A, consolidation in the pharma space given most companies are down so much they are cheap. M&A will create better synergies and better value, better pricing and CEOs know that.
With M&A ENDP stock will be double of about $27...so target is correct.
Some company can pay 100% and still get it cheap
 Earnings next few days....will again show very little cash in hand.
 Chemistry meeting May 17th is NOT going to have any trial data...think everyone knows that.
They need partnership pronto. I don't think any wk12 data will also help, as without partnership how can they even go into Phase 2/3 ?
it is NOT a scientific conference,....it is a chemistry meeting. Look it up. THERE WILL BE NO DATA COMING HERE.